Heart Test Laboratories (HSCS)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	4.05 mm	4.05 mm	4.05 mm	4.05 mm	4.05 mm	4.05 mm
Cash burn (monthly)	95.89 k	(no burn)	661.68 k	622.16 k	727.85 k	656.67 k
Cash used (since last report)	389.32 k	n/a	2.69 mm	2.53 mm	2.96 mm	2.67 mm
Cash remaining	3.66 mm	n/a	1.37 mm	1.53 mm	1.10 mm	1.39 mm
Runway (months of cash)	38.2	n/a	2.1	2.5	1.5	2.1

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

HSCS institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	3	12	-75.0%
Opened positions	0	4	EXIT
Closed positions	9	16	-43.8%
Increased positions	0	1	EXIT
Reduced positions	1	5	-80.0%

13F shares	Current	Prev Q	Change
Total value	3.08 mm	67.68 mm	-95.4%
Total shares	10.10 mm	10.64 mm	-5.1%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Matthews Holdings Southwest	5.24 mm	$786.00 k	0.0%
School Of Medicine At Mount Sinai Icahn	4.85 mm	$818.00 k	0.0%
Oliver Lagore Vanvalin Investment	305.00	$1.48 mm	-37.1%
Proequities	0.00	$0.00

Largest transactions	Shares	Bought/sold	Change
Clear Street	0.00	-269.88 k	EXIT
Citadel Advisors	0.00	-224.33 k	EXIT
Susquehanna International	0.00	-30.96 k	EXIT
UBS UBS	0.00	-9.84 k	EXIT
MS Morgan Stanley	0.00	-2.29 k	EXIT
BAC Bank of America	0.00	-791.00	EXIT
Tower Research Capital	0.00	-576.00	EXIT
Cultivar Capital	0.00	-500.00	EXIT
Oliver Lagore Vanvalin Investment	305.00	-180.00	-37.1%
JPM JPMorgan Chase & Co.	0.00	-1.00	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

HSCS insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
16 Jan 25	Andrew Simpson	Employee Stock Option Common Stock	Grant	Acquire A	No	No	3.33	45,000	149.85 k	45,000
16 Jan 25	Wells David R.	Employee Stock Option Common Stock	Grant	Acquire A	No	No	3.33	6,000	19.98 k	6,000
16 Jan 25	Danielle Watson	Employee Stock Option Common Stock	Grant	Acquire A	No	No	3.33	9,000	29.97 k	9,000
16 Jan 25	Brian Szymczak	Employee Stock Option Common Stock	Grant	Acquire A	No	No	3.33	6,000	19.98 k	6,000
16 Jan 25	Mark T Hilz	Employee Stock Option Common Stock	Grant	Acquire A	No	No	3.33	45,000	149.85 k	45,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Maxim Group Reiterates Buy on HeartSciences, Maintains $12 Price Target

18 Dec 24

Maxim Group analyst Allen Klee reiterates HeartSciences (NASDAQ:HSCS) with a Buy and maintains $12 price target.

Heart Test Laboratories Q2 EPS $(2.27) Beats $(2.43) Estimate

16 Dec 24

Heart Test Laboratories (NASDAQ:HSCS) reported quarterly losses of $(2.27) per share which beat the analyst consensus estimate of $(2.43) by 6.58 percent. This is a 85.74 percent increase over losses of $(15.92) per

Press releases

From Benzinga Pro

HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results

16 Dec 24

Southlake, TX, Dec. 16, 2024 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused